全文获取类型
收费全文 | 715篇 |
免费 | 24篇 |
国内免费 | 6篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 29篇 |
妇产科学 | 2篇 |
基础医学 | 162篇 |
口腔科学 | 9篇 |
临床医学 | 97篇 |
内科学 | 110篇 |
皮肤病学 | 15篇 |
神经病学 | 45篇 |
特种医学 | 45篇 |
外科学 | 35篇 |
综合类 | 15篇 |
预防医学 | 69篇 |
眼科学 | 36篇 |
药学 | 61篇 |
中国医学 | 1篇 |
肿瘤学 | 13篇 |
出版年
2021年 | 10篇 |
2020年 | 9篇 |
2019年 | 8篇 |
2018年 | 11篇 |
2017年 | 9篇 |
2016年 | 11篇 |
2015年 | 11篇 |
2014年 | 8篇 |
2012年 | 11篇 |
2011年 | 19篇 |
2010年 | 18篇 |
2008年 | 15篇 |
2007年 | 13篇 |
2006年 | 24篇 |
2005年 | 21篇 |
2004年 | 24篇 |
2003年 | 22篇 |
2002年 | 15篇 |
2001年 | 15篇 |
2000年 | 24篇 |
1999年 | 12篇 |
1998年 | 12篇 |
1997年 | 8篇 |
1996年 | 15篇 |
1995年 | 11篇 |
1994年 | 13篇 |
1993年 | 10篇 |
1992年 | 10篇 |
1991年 | 12篇 |
1990年 | 13篇 |
1989年 | 14篇 |
1988年 | 13篇 |
1987年 | 26篇 |
1986年 | 23篇 |
1985年 | 24篇 |
1984年 | 15篇 |
1983年 | 15篇 |
1979年 | 7篇 |
1978年 | 15篇 |
1977年 | 11篇 |
1976年 | 10篇 |
1975年 | 20篇 |
1974年 | 14篇 |
1973年 | 10篇 |
1971年 | 13篇 |
1970年 | 13篇 |
1969年 | 9篇 |
1968年 | 11篇 |
1967年 | 8篇 |
1966年 | 9篇 |
排序方式: 共有745条查询结果,搜索用时 15 毫秒
1.
2.
Activating effect of substance P on nerve tissue in culture 总被引:1,自引:0,他引:1
The effect of substance P on organotypic culture of rat sympathetic ganglia and spinal cord was studied. Substance P was able to stimulate the fibre outgrowth from explant, to increase the numbers of glial and fibroblasttypic cells in ganglia growth zone. The effect was observed in the range from 10(-5) to 10(-12) M (for sympathetic ganglia) and from 10(-5) to 10(-14) M (for spinal cord culture). It is suggested that substance P can be used as a nonspecific growth factor for peripheral and central nervous tissue. 相似文献
3.
As many as 60 patients with combined pathologies (chronic hepatitis (CH) and chronic non-calculous cholecystitis (CNCC)) were examined, and 20 healthy subjects were included in the control group. The efficacy of Essliver Forte for patients with chronic non-calculous cholecystitis combined with chronic hepatitises (both viral hepatitis and steatohepatitis) was assessed on the basis of clinical, biochemical and bacteriological criteria. Essliver Forte was found to improve the clinical and biochemical parameters of the functional liver condition, bile biochemical characteristics and intestinal microbiocenosis in patients with combined pathologies. The positive clinical effect is most evident for patients with chronic non-calculous cholecystitis and chronic steatohepatitis (both alcohol and non-alcohol). Essliver Forte can be recommended for treatment of patients with combined pathologies. 相似文献
4.
Benign intracranial hypertension and recombinant growth hormone therapy in Australia and New Zealand
PA Crock JD McKenzie AM Nicoll NJ Howard W Cutfield LK Shield G Byrne 《Acta paediatrica (Oslo, Norway : 1992)》1998,87(4):381-386
Benign intracranial hypertension (BIH) is reported in three children from Australia and one from New Zealand, who were being treated with recombinant human growth hormone (rhGH). Three males and one female, aged between 10.5 and 14.2 y, developed intracranial hypertension within 2 weeks to 3 months of starting treatment. A national database, OZGROW, has been prospectively collecting data on all 3332 children treated with rhGH in Australia and New Zealand from January 1986 to 1996. The incidence of BIH in children treated with growth hormone (GH) is small, 1.2 per 1000 cases overall, but appears to be greater with biochemical GHD (<10IUml -1 ), i.e. 6.5/1000 (3 in 465 cases), relative risk 18.4, 95% confidence interval 1.9-176.1, than in all other children on the database. The incidence in patients with Turner's syndrome was 2.3/1000 (1 in 428 cases). No cases in patients with partial GHD (10–20 IUml -1 ) or chronic renal failure were identified. Possible causative mechanisms are discussed. The authors'practice is now to start GH replacement at less than the usual recommended dose of 14IUm-2 week-1 in those children considered to be at high risk of developing BIH. Ophthalmological evaluation is recommended for children before and during the first few months following commencement of rhGH therapy and is mandatory in the event of peripheral or facial oedema, persistent headaches, vomiting or visual symptoms. The absence of papilledema does not exclude the diagnosis. 相似文献
5.
6.
7.
8.
9.
10.
Warkentin TE; Hayward CP; Boshkov LK; Santos AV; Sheppard JA; Bode AP; Kelton JG 《Blood》1994,84(11):3691-3699
Heparin-induced thrombocytopenia is characterized by moderate thrombocytopenia and thrombotic complications, whereas quinine/quinidine-induced thrombocytopenia usually presents with severe thrombocytopenia and bleeding. Using flow cytometry and assays of procoagulant activity, we investigated whether sera from patients with these immune drug reactions could stimulate normal platelets to generate platelet-derived microparticles with procoagulant activity. Sera or purified IgG from patients with heparin-induced thrombocytopenia stimulated the formation of platelet-derived microparticles in a heparin-dependent fashion. Further studies showed that heparin-induced thrombocytopenia sera also produced a marked increase in procoagulant activity. In contrast, sera from patients with quinine- or quinidine-induced thrombocytopenia did not generate platelet-derived microparticles nor generate increased procoagulant activity. However, quinine/quinidine-induced thrombocytopenia sera produced a significant increase in the binding of IgG to platelets in a drug-dependent fashion, whereas sera from patients with heparin-induced thrombocytopenia demonstrated no drug-dependent binding of IgG to platelets. We also observed increased levels of circulating microparticles in patients with acute heparin-induced thrombocytopenia compared with control patients. Our observations indicate that the generation of procoagulant platelet-derived microparticles in vivo is a plausible explanation for the thrombotic complications observed in some patients with heparin-induced thrombocytopenia. 相似文献